Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468039 | 0.84 | PDPK1 (0.52) | PDPK1ADRB2LOXL2CHEK1CYP2A6 | |
| SCHEMBL8260382 | 0.79 | PDPK1 (0.47) | PDPK1ADRB2LOXL2CHEK1CYP2A6 | |
| SCHEMBL3247666 | 0.79 | LOXL2 (0.50) | PDPK1ADRB2LOXL2CHEK1CYP2A6 | |
| SCHEMBL1460043 | 0.79 | PDPK1 (0.47) | PDPK1ADRB2LOXL2CHEK1CYP2A6 | |
| SCHEMBL29950845 | 0.77 | PDPK1 (0.44) | PDPK1ADRB2LOXL2CHEK1CYP2A6 | |
| SCHEMBL1830952 | 0.76 | ALDH1A1 (0.53) | PDPK1ADRB2LOXL2CHEK1CYP2A6 | |
| SCHEMBL3181385 | 0.76 | PDPK1 (0.47) | PDPK1ADRB2LOXL2CHEK1CYP2A6 | |
| SCHEMBL28762318 | 0.76 | PDPK1 (0.47) | PDPK1ADRB2LOXL2CHEK1CYP2A6 | |
| SCHEMBL27681353 | 0.76 | ADRB2 (0.46) | PDPK1ADRB2LOXL2CHEK1CYP2A6 | |
| SCHEMBL722198 | 0.74 | PDPK1 (0.77) | PDPK1ADRB2LOXL2CYP2A6SMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846372-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20120225883-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225883-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-06 | — | — | US | disclosed |
| US-8202999-B2 | biphenyl and pyridylphenyl derivatives such as 2,6-Difluoro-N-[2'-methyl-5'-(pyridine-3-yl)-biphenyl-4-yl]-benzamide, used as immunosuppressants for the treatmet or prevent allergies, inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202999-B2 | biphenyl and pyridylphenyl derivatives such as 2,6-Difluoro-N-[2'-methyl-5'-(pyridine-3-yl)-biphenyl-4-yl]-benzamide, used as immunosuppressants for the treatmet or prevent allergies, inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2012-06-19 | — | — | US | disclosed |
| WO-2006083477-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225883-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR8, CXCR2 | PDPK1 2955/4885ADRB2 1540/4885LOXL2 675/4885 |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR8, CXCR2 | PDPK1 2955/4885ADRB2 1540/4885LOXL2 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.